Outcomes of MAIN-COMPARE: A 10-Year Follow-Up for a Historical Rivalry

Angioplasty and myocardial revascularization surgery have competed over the left main coronary artery for a long time. There may be many points of view involved in the interpretation of trial outcomes. While surgeons consider the left main coronary artery to be suitable for surgery (except when faced with surgical contraindications), interventional cardiologists see the left main coronary artery as feasible for angioplasty, with similar outcomes in hard endpoints such as mortality.

La cirugía parece superior a la angioplastia en pacientes jóvenesThe MAIN COMPARE (Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease) registry included 2240 patients with unprotected left main coronary artery disease who underwent angioplasty (n=1102) or myocardial revascularization surgery (n=1138) between 2000 and 2006.

 

Endpoints such as death; a composite of death, infarction, or stroke; and target-vessel revascularization were compared with the use of propensity scores.


Read also: TCT 2018 | MAIN COMPARE: Angioplasty vs. Surgery for Left Main Coronary Artery Disease at 10 Years.


The follow-up was at least 10 years for all patients (median 12.0 years).

 

In the global cohort, there were no significant differences after all adjustments in the risk of death and the composite endpoint between the groups at 10 years.

 

Unsurprisingly, the risk of target-vessel revascularization was significantly higher in the angioplasty group.


Read also: EXCEL Outcomes: PCI vs CABG in Patients with Prior Cerebrovascular disease.


Comparing only patients who received drug-eluting stents, there were no significant differences in the risk of death and the composite endpoints at 5 years. However, at that timepoint, curves started to separate in favor of myocardial revascularization surgery, in terms of both mortality (hazard ratio [HR]: 1.35; 95% confidence interval [CI]: 1.00 to 1.81) and the composite endpoints (HR: 1.46; 95% CI: 1.10 to 1.94).

 

Conclusion

In patients with left main coronary artery disease, angioplasty showed similar rates of mortality and combined endpoints, but a higher rate of revascularization, at 10 years. If we only analyze the outcomes of patients who received drug-eluting stents, after 5 years, surgery outperformed angioplasty in relation to all events, including mortality.

 

Original title: 10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease.

Reference: Duk-Woo Park et al. J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2813-2822.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...